TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, March 26 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) announces today the hiring of Luc
Clouâtre as Vice-president Business Development, Sales and Marketing and and
the appointment of Dr Howard Maibach as Scientific Advisor.
Mr. Luc Clouâtre will be responsible for all global commercial activities
at Advitech with a strong focus on the U.S. market for existing products
(Dermylex(R), Microdermabrasion lines and Growth Factors) and will lead
company's growth in new opportunities generated by the Wound Healing platform.
Mr. Luc Clouâtre was from 1998 to 2006 the Chief Executive Officer of
Pierre Fabre Group ( U.S operations, Las Vegas Nevada) and until February 2008
the Chief Executive Officer of Cosmedx Science ( Los Angeles, California). He
brings more than 20 years of experience in the commercialization of
nutraceutical and pharmaceutical products.
"With the addition of Mr. Clouâtre, we now have the resources and depth
to increase our sales and rapidly implement strategies and activities to
capture new market opportunities linked to our product portfolio. Also we're
implementing an aggressive sales and marketing plan on major markets such as
the United States and Europe" commented Renaud Beauchesne, President and Chief
Executive officer at Advitech.
Advitech has also appointed Dr Howard Maibach as a scientific advisor to
the Company. Mr. Maibach has been a Professor in the Deparment of Dermatology
since 1973 at University of San Francisco, CA., and is internationally
recognized as a leading researcher in psoriasis and wound healing.
Dr. Maibach has been on the editorial boards of over 30 scientific
journals and is a member of 19 professional societies including the American
Academy of Dermatology, the San Francisco Dermatological Society, and the
International Commission on Occupational Health.
About Growth factors:
Growth factors are proteins with multiple functions in the human body.
Growth factors modulate immune responses and cell growth. Some growth factors
are produced in the laboratory and used in biological therapy in extremely
lucrative markets such as inflammatory diseases or skin care. However,
synthetic production of growth factors is extremely expensive, which
represents a major concern for product development.
Through an extensive research program, Advitech has mastered the ability
to produce naturally milk derived growth factors at relatively lower cost than
synthetic growth factors. The ability of Advitech to produce such growth
factors opens up new market opportunities in the nutraceutical and
About Wound Healing:
According to Espicom Business Intelligence Ltd., the global wound care
market totalled $7.2 billion in 2006, with a 10% growth rate. Growth factors
based applications for wound healing represent more than 5% of the market,
with an impressive 27% growth rate.
About Dermylex(R) www.dermylex.com:
Dermylex(R), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(R) for that type of psoriasis. Dermylex(R) is currently available in
Canada and the U.S. (as BioDerm, Dermalyx(R)), as well as in France and
Belgium (as Psopax(R)).
About Advitech Inc. www.advitech.com:
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
Advitech has structured a research program to develop new applications
related to wound healing predicated upon both its XP-828L and IM technological
This press release contains forward-looking statements which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The TSX Venture Exchange
does not accept responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Renaud Beauchesne, MBA, President and Chief
Executive Officer, Advitech Inc., (418) 686-7498 x228, email@example.com,
www.advitech.com; Serge Comeau, Investor Relations, Advitech Inc., Direct
Line: (514) 862-4160, firstname.lastname@example.org, www.advitech.com